Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer

Open access
Jover, Rodrigo, Nguyen, Thuy–Phuong, Pérez–Carbonell, Lucía, Zapater, Pedro, Payá, Artemio, Alenda, Cristina, Rojas, Estefanía, Cubiella, Joaquín, Balaguer, Francesc, Morillas, Juan D., Clofent, Juan, Bujanda, Luis, Reñé, Josep M., Bessa, Xavier, Xicola, Rosa M., Nicolás–Pérez, David, Castells, Antoni, Andreu, Montserrat, Llor, Xavier, Boland, C. Richard, Goel, Ajay·2011·Gastroenterology

Abstract

Background & Aims 5-FU-based adjuvant chemotherapy does not increase survival times of patients with colorectal tumors with microsatellite instability. We determined the response of patients with colorectal tumors with the CpG island methylator phenotype (CIMP) to 5-FU-based therapy. Methods We analyzed a population-based cohort of 302 patients with colorectal cancer (CRC) for a median follow-up time of 50.7 months. CIMP status was determined by analysis of the CACNAG1, SOCS1, RUNX3, NEUROG1, and MLH1 promoters; tumors were considered to be CIMP-positive (CIMP+) if at least 3 promoters were methylated. Results Tumors from 29.5% (89/302) of patients were CIMP+; this did not influence disease-free survival (log rank=.26). Of tumors of TNM stages II–III (n=196), 32.7% were CIMP+. Among patients with CRC stages II–III who did not receive adjuvant 5-FU chemotherapy, those with CIMP+ tumors had longest times of disease-free survival (log rank=.04); patients with CIMP+ tumors who received chemotherapy had shorter times of disease-free survival (log rank=0.02). In patients with CIMP-negative tumors, adjuvant 5-FU chemotherapy significantly increased time of disease-free survival (log-rank=.00001). However, in patients with CIMP+ tumors, adjuvant 5-FU chemotherapy did not affect time of disease-free survival (log rank=.7). Multivariate analysis showed a significant, independent interaction between 5-FU treatment and CIMP status (hazard ratio [HR]=0.6; 95% confidence interval [CI], .5–.8). Among patients with CIMP+ tumors, adjuvant chemotherapy was not an independent predictor of outcome (HR=0.8; 95% CI, 0.3–2.0). In patients who did not receive adjuvant 5-FU chemotherapy, CIMP status was the only independent predictor of survival (HR=2.0; 95% CI, 1.1–3.8) Conclusion Patients with CIMP+ colorectal tumors do not benefit from 5-FU–based adjuvant chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2010.12.035

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 205

Metadata

Authors
Jover, R., Nguyen, T., Pérez–Carbonell, L., Zapater, P., Payá, A., Alenda, C., Rojas, E., Cubiella, J., Balaguer, F., Morillas, J. D., Clofent, J., Bujanda, L., Reñé, J. M., Bessa, X., Xicola, R. M., Nicolás–Pérez, D., Castells, A., Andreu, M., Llor, X., Boland, C. R., & Goel, A.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2011-04
Volume
140
Issue
4
Pages
1174-1181
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2163975490
Cited by
205
References
3
FWCI
9.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. https://app.cochat.ai/papers/10.1053/j.gastro.2010.12.035
The paper
Jover, R., Nguyen, T., Pérez–Carbonell, L., Zapater, P., Payá, A., Alenda, C., Rojas, E., Cubiella, J., Balaguer, F., Morillas, J. D., Clofent, J., Bujanda, L., Reñé, J. M., Bessa, X., Xicola, R. M., Nicolás–Pérez, D., Castells, A., Andreu, M., Llor, X., . . . Goel, A. (2011). 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology. https://doi.org/10.1053/j.gastro.2010.12.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.